Soligenix (NASDAQ: SNGX) , a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. Th ...

Trauma doesn't wait, and neither should treatment. Despite advancements in emergency medical services, 42% of hemorrhaging ...

Traws Pharma, Inc. ( NASDAQ: TRAW) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant Iain D. Dukes - ...

Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage trial, ...

Doctors and scientists who spoke to HuffPost are worried for a multitude of reasons and want you to know that this will ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Reports Q2 revenue $2.7M vs. $57,000 last year. “Traws has made good progress this year towards our goal of bringing our antiviral candidates to ...

The Trump administration’s decision to halt nearly $500 million for mRNA vaccine research has made investors more hesitant to ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door ...

Director Jay Bhattacharya claims the federal government recently canceled millions of dollars’ worth of mRNA research ...

HealthSecretary Robert F. Kennedy Jr. has defunded research in messenger RNA vaccines, which could jeopardize efforts to ...